KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Exchange Rate Effect (2016 - 2025)

Opko Health (OPK) has disclosed Exchange Rate Effect for 16 consecutive years, with $174000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 103.13% year-over-year to $174000.0, compared with a TTM value of $3.4 million through Dec 2025, up 208.62%, and an annual FY2025 reading of $3.4 million, up 208.62% over the prior year.
  • Exchange Rate Effect was $174000.0 for Q4 2025 at Opko Health, up from -$316000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $2.6 million in Q3 2024 and bottomed at -$5.6 million in Q4 2024.
  • Average Exchange Rate Effect over 5 years is -$58736.8, with a median of $174000.0 recorded in 2025.
  • The sharpest move saw Exchange Rate Effect skyrocketed 407.69% in 2023, then plummeted 868.46% in 2024.
  • Year by year, Exchange Rate Effect stood at -$1.3 million in 2021, then soared by 233.52% to $1.7 million in 2022, then tumbled by 57.5% to $723000.0 in 2023, then tumbled by 868.46% to -$5.6 million in 2024, then surged by 103.13% to $174000.0 in 2025.
  • Business Quant data shows Exchange Rate Effect for OPK at $174000.0 in Q4 2025, -$316000.0 in Q3 2025, and $1.5 million in Q2 2025.